US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Peptonic Medical AB announces a new date for the publication of its annual report

Peptonic Medical AB (publ) announces that the company has decided to postpone the publication of its annual report for the 2025 financial year.The previously announced publication date was 3 June 2026. The new publication date is 10 June 2026. The annual report will be published on the company’s website as soon as it is finalised. For further information, please contact: Daniel Rudeklint, Interim CEO, Peptonic Medical AB Email: daniel.rudeklint@peptonicmedical.se Telephone: +46 73 158 02 73 About Peptonic Medical AB Peptonic Medical AB (publ) is a Swedish medical

Peptonic Medical launches a new product segment in health and beauty – strengthening growth opportunities through a broader offering and a new brand

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is launching a new product segment within health and beauty. This initiative represents a significant broadening of the Company’s product portfolio and constitutes an important step in the long-term strategy to create new revenue streams and strengthen the market position. The launch is planned for the second half of 2026. In connection with this, the Company will also bring products together under a new common brand in accordance with the strategic development plan.The first product will be an innovative dietary supplement developed

The subscription price for warrants of series TO6 in Peptonic has been determined to SEK 0.0011 and the exercise period begins today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.Peptonic Medical AB ("Peptonic" or the "Company") completed during the first quarter of 2026 a rights issue of units, consisting of shares and warrants of series TO6 (the "Warrants" or “TO6”). The subscription price for the Warrants has been determined to SEK 0.

Peptonic Medical nears first delivery to strategic partner in the US – a key milestone in its international expansion

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is now nearing its first delivery under the Company’s partnership agreement in the US with an established American player in the field of intimate self-care for women during and after the menopause. The agreement, which Peptonic has previously announced, covers the US, Canadian, Mexican and UK markets and involves Peptonic supplying products that are marketed and sold under the partner’s own well-known brand.The first order, with an initial value of USD 120,000, was received in October 2025, and work on product design and delivery

Peptonic Medical AB (publ) - Publishes financial report for the first quarter 2026

Peptonic Medical AB (publ) ("Peptonic" or the "Company") publishes today, May27, 2026, financial report for the first quarter2026.Key figures for the Group – First quarter (January - March) · Sales of goods amounted to KSEK 3 138 (3 758). · Gross profit amounted to KSEK 2 121 (2 165), corresponding to a gross margin of 68 (58) percent. · Operating profit amounted to KSEK -5 330 (-7 459). · Earnings per share amounted to SEK -0,0005 (-0,001).   Key figures for the Mother company - First quarter (January - March) · Sales of goods amounted to KSEK 3 138 (3 302). ·

NOTICE OF THE ANNUAL GENERAL MEETING OF PEPTONIC MEDICAL AB

The shareholders of Peptonic Medical AB (publ), corporate ID no. 556776–3064 (“the Company” or “Peptonic”), are hereby invited to the Annual General Meeting on June 24, 2026, at 10:00 a.m. at the offices of Eversheds Sutherland, Sveavägen 20 in Stockholm. Registration begins at9:45 a.m.ELIGIBILITY AND REGISTRATION Shareholders who wish to attend the Annual General Meeting must• be listed in the share register maintained by Euroclear Sweden AB as of June 15, 2026,• and notify Peptonic Medical AB in writing of their intention to attend no later than June 17, 2026, Färögatan 33,

Peptonic Medical Launches VagiVital Moisturizing Intimate Cream, Further Expanding Its Portfolio of Moisturizing Intimate Care Products

Peptonic Medical (publ) (“Peptonic” or “the Company”) is expanding its product portfolio in the field of intimate care and launching VagiVital Moisturizing Intimate Cream, a moisturizing intimate cream specifically developed for external application to the vulva. The product is aimed at women who experience dryness and discomfort in the external areas of the intimate region and represents a strategically important addition to VagiVital’s growing premium range in modern intimate care.The launch is part of Peptonic’s long-term strategy to establish VagiVital as a leading, comprehensive brand

Peptonic Medical is expanding its portfolio in the intimate self-care category and launching VagiVital Intimate V Wipes

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is expanding its product portfolio in the intimate health category and launching VagiVital Intimate V Wipes, intimate wipes specially developed for gentle cleansing of the external areas of the intimate region. The launch is part of Peptonic’s strategy to develop VagiVital into a stronger and broader brand in intimate care, with products for a variety of everyday needs.The launch is a strategically important step in Peptonic’s ambition to develop VagiVital into a leading, comprehensive brand in intimate self-care, with products that

Peptonic postpones the Annual General Meeting and publication of the annual report

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Board of Directors has postponed the Annual General Meeting and the publication of the annual report for 2025. The annual report will be published on June 3, 2026 and the Annual General Meeting will be held on June 24, 2026.Previously communicated dates according to the Company’s financial calendar were the publication of the annual report on May 20, 2026 and the Annual General Meeting on June 10, 2026. The postponement is due to administrative reasons. For further information, please contact: Daniel Rudeklint,

Peptonic provides an update on Vernivia

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces a regulatory update regarding Vernivia®. The Company has now finalised the relevant interim reports with its Notified Body, which constitutes a crucial step in the ongoing MDR process for updating the CE marking.Vernivia is a unique, patented product targeting the major problem of bacterial vaginosis. Vernivia is the first clinically proven, antibiotic-free self-care treatment that provides rapid symptom relief, treats the vaginal infection and simultaneously stimulates the growth of protective lactobacilli. The product has

Peptonic Medical AB (publ) - Publishes Year-end report for 2025

Peptonic Medical AB (publ) ("Peptonic" or the "Company") publishes today, February 27, 2026, its year-end report for 2025.Key figures for the Group - Fourth quarter (October – December) · Sales of goods amounted to KSEK 3,539 (4,445). · Gross profit amounted to KSEK 2,165 (2,563), corresponding to a gross margin of 61 (58) percent. · Operating profit amounted to KSEK 998 (-26,749). · Earnings per share amounted to SEK 0.0000001 (-0.005).   Key figures for the Group - Twelve months (January – December) · Sales of goods amounted to KSEK 14,788 (26,891). · Gross

Peptonic Medical AB - Board of Directors appoints Daniel Rudeklint as interim CEO

Peptonic Medical AB (publ) ("Peptonic") announces the appointment of Daniel Rudeklint as interim CEO with immediate effect. Daniel Rudeklint replaces Anna Linton as CEO.Daniel Rudeklint has been in Peptonic's board since January 2023 and has a strong financial background, very good insight into the company and solid experience in leading organizations. The work of recruiting a new permanent CEO is ongoing. "On behalf of the board of directors, I thank Anna for the work she has done during the past years as CEO of Peptonic and how she has shown commitment and loyalty to the company," says

Peptonic Medical AB announces termination of liquidity provider agreement

Peptonic Medical AB (publ) (the “Company”) announces that the Company has terminated its agreement with Mangold Fondförvaltning AB regarding the assignment as liquidity provider.The purpose of the liquidity provider arrangement has been to promote liquidity in the Company’s share, reduce volatility and facilitate trading. The Company assesses that the current trading and liquidity in the share are satisfactory and that the benefit of a liquidity provider is therefore limited. The liquidity provider arrangement ceased after the close of trading on 23 February 2026. For more information

Peptonic announces the last day of trading in BTU and first day of trading in TO6 warrants

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the rights issue of units consisting of shares and warrants, which formed part of the restructuring measures under

Peptonic’s Board of Directors resolves on a directed issue of units to guarantors in connection with the completed rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) ("Peptonic" or the "Company") has, as previously announced, completed the rights issue of units consisting of shares and warrants with preferential rights for

Peptonic Medical AB announces outcome of the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) ("Peptonic" or the "Company") today announces the outcome of the rights issue of units, consisting of shares and warrants of series TO6, which formed part of

Peptonic Medical AB changes date for publication of year-end report

Peptonic Medical AB (publ) (“the Company”) announces a changed date for the publication of the Q4 report and also the year-end report for 2025 from February 25, 2026 to February 27, 2026.For further information, please contact:Anna Linton, CEO, Peptonic Medical AB                                            Email: anna.linton@peptonicmedical.se                                                                                      Phone: +46 70-244 92 07 About Peptonic Medical AB                                         PEPTONIC medical AB (publ) is a pioneering Swedish Medical

Last day of trading with unit rights in Peptonic’s rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, 23 January 2026, is the last day of trading with the unit rights in Peptonic Medical AB’s (publ) ("Peptonic" or the "Company") rights issue of units, consisting of shares and

The subscription period in Peptonic’s rights issue of units starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, 14 January 2026, the subscription period begins in Peptonic Medical AB (publ) (”Peptonic” or the “Company”) rights issue of units, consisting of shares and warrants, which forms

Peptonic publishes prospectus in connection with rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) (”Peptonic” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) in connection with the Company’s forthcoming rights issue of units,

Peptonic Medical AB. Corporate reconstruction formally concluded following dismissal decision

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has dismissed the corporate reconstruction proceedings. The dismissal decision means that the corporate reconstruction is thereby formally and legally concluded.The conclusion of the reconstruction entails that the Company returns to ordinary operations and continues the implementation of the measures set out in the reconstruction plan. The dismissal decision will be made available on the Company’s website:https://www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025/ For further

Peptonic Medical AB’s Reconstruction plan becomes legally binding and the reconstruction is concluded

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Company’s reconstruction plan, which was confirmed by the Uppsala District Court on 28 November 2025, has now become legally binding. As a result, the corporate reconstruction process has been concluded. The Company will now proceed with the implementation of the reconstruction measures set out in the reconstruction plan.The confirmed reconstruction measures include, among other things: · A directed set-off issue and a rights issue, both to be carried out within two months from the date on which the

Peptonic Medical AB clarifies expected conclusion of its corporate reconstruction

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) clarifies the next steps in the reconstruction process and when the Company’s corporate reconstruction is expected to conclude, following the approval of the reconstruction plan by the Uppsala District Court on 28 November 2025. In connection with the court’s decision, it was also determined that the corporate reconstruction will terminate on the date the reconstruction plan becomes legally binding.The decision to approve the reconstruction plan replaces the District Court’s previous decision to extend the corporate reconstruction

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe